JP2024519904A5 - - Google Patents
Info
- Publication number
- JP2024519904A5 JP2024519904A5 JP2023571882A JP2023571882A JP2024519904A5 JP 2024519904 A5 JP2024519904 A5 JP 2024519904A5 JP 2023571882 A JP2023571882 A JP 2023571882A JP 2023571882 A JP2023571882 A JP 2023571882A JP 2024519904 A5 JP2024519904 A5 JP 2024519904A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- seq
- cd40l
- sequence number
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163191514P | 2021-05-21 | 2021-05-21 | |
| US63/191,514 | 2021-05-21 | ||
| US202163235520P | 2021-08-20 | 2021-08-20 | |
| US63/235,520 | 2021-08-20 | ||
| PCT/US2022/030290 WO2022246225A1 (en) | 2021-05-21 | 2022-05-20 | Cd40l antagonist and uses thereof in the treatment of lupus nephritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024519904A JP2024519904A (ja) | 2024-05-21 |
| JP2024519904A5 true JP2024519904A5 (enExample) | 2025-05-22 |
Family
ID=82100122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023571882A Pending JP2024519904A (ja) | 2021-05-21 | 2022-05-20 | Ｃｄ４０ｌアンタゴニスト及びループス腎炎の治療におけるその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240084024A1 (enExample) |
| EP (1) | EP4340867A1 (enExample) |
| JP (1) | JP2024519904A (enExample) |
| KR (1) | KR20240012473A (enExample) |
| AU (1) | AU2022276507A1 (enExample) |
| BR (1) | BR112023024153A2 (enExample) |
| CA (1) | CA3219742A1 (enExample) |
| IL (1) | IL308488A (enExample) |
| MX (1) | MX2023013815A (enExample) |
| WO (1) | WO2022246225A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20260217842A1 (en) * | 2023-01-13 | 2026-07-30 | Viela Bio, Inc. | Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjögren's syndrome |
| KR20250162587A (ko) * | 2023-03-28 | 2025-11-18 | 비엘라 바이오, 인크. | 쇼그렌 증후군의 치료 및 예방을 위한 cd40l 특이적 tn3 유래 스캐폴드 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130006640A (ko) * | 2010-03-03 | 2013-01-17 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드를 이용한 루푸스 신장염의 치료 |
| KR102434073B1 (ko) * | 2011-10-11 | 2022-08-18 | 비엘라 바이오, 인크. | Cd40l 특이적 tn3 유래 스카폴드 및 이의 사용 방법 |
| CN116196414A (zh) * | 2015-05-11 | 2023-06-02 | 豪夫迈·罗氏有限公司 | 治疗狼疮性肾炎的组合物和方法 |
| US10286036B2 (en) * | 2017-05-12 | 2019-05-14 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
| KR102919125B1 (ko) * | 2018-09-26 | 2026-01-27 | 비엘라 바이오, 인크. | Cd40l 길항제 및 이의 용도 |
-
2022
- 2022-05-20 CA CA3219742A patent/CA3219742A1/en active Pending
- 2022-05-20 AU AU2022276507A patent/AU2022276507A1/en active Pending
- 2022-05-20 KR KR1020237043917A patent/KR20240012473A/ko active Pending
- 2022-05-20 JP JP2023571882A patent/JP2024519904A/ja active Pending
- 2022-05-20 IL IL308488A patent/IL308488A/en unknown
- 2022-05-20 WO PCT/US2022/030290 patent/WO2022246225A1/en not_active Ceased
- 2022-05-20 MX MX2023013815A patent/MX2023013815A/es unknown
- 2022-05-20 EP EP22731386.3A patent/EP4340867A1/en active Pending
- 2022-05-20 BR BR112023024153A patent/BR112023024153A2/pt unknown
-
2023
- 2023-11-15 US US18/509,836 patent/US20240084024A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2423281T3 (es) | Tratamiento de la enfermedad de Alzheimer | |
| US12173045B2 (en) | Human alpha fetoprotein-specific t cell receptors and uses thereof | |
| AU2008255556B2 (en) | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues | |
| US9365634B2 (en) | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues | |
| JP2020169191A5 (enExample) | ||
| JP2022169589A5 (enExample) | ||
| JP2023103368A5 (enExample) | ||
| BR112019013215A2 (pt) | vírus oncolítico, composição farmacêutica, produto de fabricação, método para tratar câncer e uso | |
| RU2005127429A (ru) | Активная иммунизация для создания антител к растворимому а-бета | |
| KR20080055932A (ko) | 태반 성장 인자 매개된 전이 및/또는 혈관신생의 억제 | |
| CN113072623B (zh) | 一种靶向SARS-CoV-2 N蛋白的干扰肽的制备方法及应用 | |
| JP2020509737A5 (enExample) | ||
| JP2003530360A (ja) | 薬剤送達のためのペプチド複合体 | |
| JP2023500248A5 (enExample) | ||
| JP2024525795A5 (enExample) | ||
| JP2024511970A5 (enExample) | ||
| JP2023542297A5 (enExample) | ||
| JP2022544053A5 (enExample) | ||
| JP2852705B2 (ja) | 自己免疫疾患の治療 | |
| CN1154659C (zh) | 新的抗艾滋病免疫毒素 | |
| CN1345336A (zh) | 抗体和趋化因子构建物及其在自身免疫疾病治疗中的用途 | |
| WO2007119447A1 (ja) | 関節リウマチの処置剤 | |
| JP2026506447A (ja) | 呼吸器合胞体ウイルスｍＲＮＡワクチン | |
| JP2023515806A5 (enExample) | ||
| JP2024535431A5 (enExample) |